Background: Cutaneous neoplasms include melanoma and non-melanoma skin cancers (NMSCs). Among NMSCs, basal cell carcinoma (BCC) represents the most common lesion. On the contrary, although accounting for less than 5% of all skin cancers, melanoma is responsible for most of cutaneous malignancy-related deaths. Paraoxonase-2 (PON2) is an intracellular enzyme exerting a protective role against production of reactive oxygen species within mitochondrial respiratory chain. Recently, a growing attention has been focused on exploring the role of PON2 in cancer. The aim of this study was to investigate the diagnostic and prognostic role of PON2 in skin neoplasms. Materials and methods: 36 cases of BCC, distinguished between nodular and infiltrative lesions, as well as 29 melanoma samples were analysed by immunohistochemistry to evaluate PON2 protein expression. Subsequent statistical analyses were carried out to explore the existence of correlations between intratumour enzyme levels and clinicopathological features. Results: Results obtained showed PON2 overexpression in BCCs compared with controls. In particular, distinguishing between less and more aggressive tumour forms, we found no significant differences in enzyme levels between nodular BCCs and controls. Conversely, PON2 expression was significantly higher in infiltrative BCCs compared with controls. Moreover, the enzyme was strongly upregulated in melanoma samples with respect to controls. Interestingly, PON2 levels were positively correlated with Breslow thickness, Clark level, regression, mitoses, lymph node metastases, primary tumour (pT) parameter and pathological stage. Conclusions: Reported findings seem to suggest that PON2 expression levels could be positively related with tumour aggressiveness of both BCC and melanoma.

Paraoxonase-2: A potential biomarker for skin cancer aggressiveness / Bacchetti, T; Salvolini, E; Pompei, V; Campagna, R; Molinelli, E; Brisigotti, V; Togni, L; Lucarini, G; Sartini, D; Campanati, A; Mattioli-Belmonte, M; Rubini, C; Ferretti, G; Offidani, A; Emanuelli, M. - In: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. - ISSN 1365-2362. - STAMPA. - 51:5(2021). [10.1111/eci.13452]

Paraoxonase-2: A potential biomarker for skin cancer aggressiveness

Bacchetti T;Salvolini E;Pompei V;Campagna R;Molinelli E;Brisigotti V;Togni L;Lucarini G;Sartini D;Campanati A;Mattioli-Belmonte M;Rubini C;Ferretti G;Offidani A;Emanuelli M
2021-01-01

Abstract

Background: Cutaneous neoplasms include melanoma and non-melanoma skin cancers (NMSCs). Among NMSCs, basal cell carcinoma (BCC) represents the most common lesion. On the contrary, although accounting for less than 5% of all skin cancers, melanoma is responsible for most of cutaneous malignancy-related deaths. Paraoxonase-2 (PON2) is an intracellular enzyme exerting a protective role against production of reactive oxygen species within mitochondrial respiratory chain. Recently, a growing attention has been focused on exploring the role of PON2 in cancer. The aim of this study was to investigate the diagnostic and prognostic role of PON2 in skin neoplasms. Materials and methods: 36 cases of BCC, distinguished between nodular and infiltrative lesions, as well as 29 melanoma samples were analysed by immunohistochemistry to evaluate PON2 protein expression. Subsequent statistical analyses were carried out to explore the existence of correlations between intratumour enzyme levels and clinicopathological features. Results: Results obtained showed PON2 overexpression in BCCs compared with controls. In particular, distinguishing between less and more aggressive tumour forms, we found no significant differences in enzyme levels between nodular BCCs and controls. Conversely, PON2 expression was significantly higher in infiltrative BCCs compared with controls. Moreover, the enzyme was strongly upregulated in melanoma samples with respect to controls. Interestingly, PON2 levels were positively correlated with Breslow thickness, Clark level, regression, mitoses, lymph node metastases, primary tumour (pT) parameter and pathological stage. Conclusions: Reported findings seem to suggest that PON2 expression levels could be positively related with tumour aggressiveness of both BCC and melanoma.
2021
File in questo prodotto:
File Dimensione Formato  
EJCI 2021.pdf

Solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza d'uso: Tutti i diritti riservati
Dimensione 1.92 MB
Formato Adobe PDF
1.92 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
ejci+R2.pdf

Open Access dal 03/12/2021

Descrizione: This is the peer reviewed version of the following article: Paraoxonase-2: A potential biomarker for skin cancer aggressiveness / Bacchetti, T; Salvolini, E; Pompei, V; Campagna, R; Molinelli, E; Brisigotti, V; Togni, L; Lucarini, G; Sartini, D; Campanati, A; Mattioli-Belmonte, M; Rubini, C; Ferretti, G; Offidani, A; Emanuelli, M. - In: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. - ISSN 1365-2362. - STAMPA. - 51:5(2021). © 2020 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd, which has been published in final form at https://doi.org/10.1111/eci.13452. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions https://authorservices.wiley.com/author-resources/Journal-Authors/licensing/self-archiving.html. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.
Tipologia: Documento in post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza d'uso: Licenza specifica dell’editore
Dimensione 5.29 MB
Formato Adobe PDF
5.29 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/285972
Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 32
social impact